Merck (MRK) Delivers Strong Q3 2025 Earnings as Oncology Sales Drive Revenue Growth

Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing better-than-expected financial results despite uneven product portfolio performance. The company’s revenue of $17.3 billion crossed analyst estimates of $16.98 billion, while its EPS of $2.58 considerably surpassed analyst projections of $2.35.

Merck’s oncology division remains the main driver of growth, led by KEYTRUDA’s $8.1 billion in sales for the quarter. Other oncology medications also showed solid results, with WELIREG sales jumping 41% to $196 million, Lynparza sales rising 12% to $379 million, and Lenvima sales growing 2% to $258 million.

The FDA’s approval of subcutaneous pembrolizumab (KEYTRUDA QLEX) for all solid tumor indications that had previously been approved for intravenous KEYTRUDA was a major regulatory milestone during the quarter. This formulation may enhance the patient experience, given that it can be administered in as little as one minute.

That said, Merck & Co. Inc. (NYSE:MRK) saw substantial challenges in its vaccines division, as GARDASIL sales fell 25% to $1.7 billion, primarily as a result of a decline in Chinese sales.

Merck & Co. Inc. (NYSE:MRK) is a healthcare company that offers human health pharmaceuticals, veterinary pharmaceuticals, vaccines & health management solutions and services.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.